NEW YORK and SYDNEY, Australia, August 11, 2020 - Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), is pleased to announce that further to its announcement on August 4, 2020 regarding the development of a medical solution utilizing nanobody technology for COVID-19, it has just signed an agreement with GenScript ProBio.
GenScript ProBio will render the services based on 3 phases: (1) Perform pseudovirus neutralization assay with candidate antibody (2) Production and characterization of humanized antibodies and (3) Using PML (Precise Mutagenesis Library) and FASEBA (Fast Screening for Expression, Biophysical-Properties and Affinity) to carry out affinity maturation and purification of the antibodies. The process is expected to take 15-18 weeks.
Jacky Zhang, Chairman and CEO of Beroni Group, said, “We are pleased to be able to work with GenScript ProBio, to use their leading CDMO platform to further advance our study into the use of nanobodies for treating COVID-19 patients. Nanobody, which has more natural advantages than traditional antibody, is more suitable as a neutralizing antibody to treat coronavirus patients. Nanobody treatment is fast emerging as an effective antibody drug in the market. We will do our utmost best to accelerate our clinical study so that we can produce a timely, safe and effective medical solution to help stop the global spread of this infectious disease.”
Brian Min,CEO of GenScript ProBio, said, “COVID-19 is still on the rise globally. During this period, we are pleased to collaborate with Beroni Group to use our CDMO platform to facilitate research on nanobodies for the treatment of COVID-19 patients.It is believed that with our joint efforts, this technology can appear in the market as soon as possible for the benefit of patients.”
Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.